Sawyer & Company Inc Sells 3,076 Shares of Cencora, Inc. (NYSE:COR)

Sawyer & Company Inc trimmed its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,039 shares of the company's stock after selling 3,076 shares during the period. Sawyer & Company Inc's holdings in Cencora were worth $2,031,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of COR. Pacer Advisors Inc. increased its holdings in Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock worth $464,874,000 after buying an additional 2,035,679 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Cencora by 136.8% during the 2nd quarter. Bank of Montreal Can now owns 641,887 shares of the company's stock worth $153,623,000 after purchasing an additional 370,841 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Cencora by 7.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after purchasing an additional 338,452 shares during the period. Nordea Investment Management AB lifted its stake in Cencora by 40.2% in the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after purchasing an additional 308,773 shares during the last quarter. Finally, Two Sigma Advisers LP grew its holdings in Cencora by 21.7% during the third quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock worth $368,771,000 after purchasing an additional 292,600 shares during the period. Institutional investors own 97.52% of the company's stock.

Cencora Stock Performance

Cencora stock traded up $2.84 during midday trading on Thursday, hitting $240.51. The company's stock had a trading volume of 862,781 shares, compared to its average volume of 1,259,068. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company has a market cap of $46.49 billion, a price-to-earnings ratio of 32.03, a PEG ratio of 1.48 and a beta of 0.49. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $253.27. The company has a 50-day moving average price of $237.65 and a two-hundred day moving average price of $233.72.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.91%. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora's payout ratio is presently 29.29%.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,678 shares of the company's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 94,696 shares of company stock worth $22,862,734. Company insiders own 15.80% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on COR shares. StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Wells Fargo & Company dropped their price target on Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a research note on Friday, December 13th. Leerink Partners reduced their price objective on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research report on Monday, October 7th. Evercore ISI increased their price objective on shares of Cencora from $250.00 to $285.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. Finally, UBS Group lifted their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Cencora has an average rating of "Moderate Buy" and an average price target of $275.60.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.